Reverse phase, ion exchange, HILIC and mix-mode chromatography for the determination of metformin and evogliptin in human plasma and pharmaceutical formulations

Reverse phase, ion exchange, HILIC and mix-mode chromatography for the determination of metformin and evogliptin in human plasma and pharmaceutical formulations

Separation and quantification of highly polar metformin (MTF) alone or in combination with dipeptidyl peptidase-4 inhibitors, such as evogliptin (EVG), sitagliptin, saxagliptin, vildagliptin, linagliptin and teneligliptin, specifically from human plasma and pharmaceutical products is still difficult...

Full description

Bibliographic Details
Main Authors:	Pankaj M. Kharabe, Prasad P. Jumade, Pravin N. Khatale, Parimal P. Katolkar, Santosh R. Butle, Mahendra D. Kshirsagar, Vishal V. Pendharkar, Amol V. Sawale, Kalyani S. Choudhari
Format:	Article
Language:	English
Published:	Elsevier 2024-08-01
Series:	Talanta Open
Subjects:	Dipeptidyl peptidase-4 inhibitors Evogliptin Sitagliptin Saxagliptin Vildagliptin Linagliptin
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666831923000942

Similar Items

Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
by: Chiranjib Chakraborty, et al.
Published: (2017-01-01)

DIPEPTIDYL DIPEPTIDASE-4: VIEW OF THE CLINICAL PHARMACOLOGIST
by: N. B. LAZAREVA
Published: (2016-12-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
by: Nasser Mikhail
Published: (2008-12-01)

Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial
by: Alina Y. Babenko, et al.
Published: (2018-09-01)

Minimum Effective Dose of DPP-4 Inhibitors for Treating Early Stages of Diabetic Retinopathy in an Experimental Model
by: Patricia Bogdanov, et al.
Published: (2022-02-01)

Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus
by: Cobble Michael
Published: (2012-03-01)

Long-term use of dipeptyl peptidase-4 inhibitors suppresses systemic oxidative stress in rats with type 2 diabetes
by: S. S. Bolevich, et al.
Published: (2019-12-01)

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
by: Manash P Baruah, et al.
Published: (2016-01-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01)

Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01)

Saxagliptin for type 2 diabetes
by: Chacra
Published: (2010-09-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses
by: Kannan Sridharan, et al.
Published: (2025-01-01)

The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain
by: Pyung Goo Cho, et al.
Published: (2023-11-01)

A case of irritant contact dermatitis and suspected linagliptin-induced koebnerized bullous pemphigoid
by: Austin Ambur, DO, et al.
Published: (2020-04-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Fabrication of novel vildagliptin loaded ZnO nanoparticles for anti diabetic activity
by: Abdul Samad, et al.
Published: (2024-08-01)

The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
by: Naoyuki Kitao, et al.
Published: (2017-10-01)

Evaluation of the Drug-Induced Liver Injury Potential of Saxagliptin through Reactive Metabolite Identification in Rats
by: Ki-Young Kim, et al.
Published: (2024-01-01)

Post-marketing Study of Linagliptin: A Pilot Study
by: Gabrielle Kéfrem Alves Gomes, et al.
Published: (2019-05-01)

Linagliptin is associated to increased treatment adherence and satisfaction in elderly outpatients with diabetes and advanced chronic kidney disease
by: Franco Gregorio, et al.
Published: (2016-11-01)

Ocular and Plasma Pharmacokinetics of Sitagliptin Eye Drops: Preclinical Data
by: Cristina Hernández, et al.
Published: (2024-11-01)

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
by: Shin Y, et al.
Published: (2022-12-01)

Combined saline and vildagliptin induced M2 macrophage polarization in hepatic injury induced by acute kidney injury
by: Shaimaa N. Amin, et al.
Published: (2023-02-01)

The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis
by: Qizhi Tang, et al.
Published: (2022-08-01)

Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
by: Anna A. Mosikian, et al.
Published: (2018-11-01)

Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification
by: Bongkun Choi, et al.
Published: (2021-01-01)

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy
by: Hugo Ramos, et al.
Published: (2022-07-01)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
by: Ahren B
Published: (2010-03-01)

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
by: Rhee SJ, et al.
Published: (2016-08-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al.

Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
by: Rhee SJ, et al.
Published: (2016-04-01)

Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
by: D. V. Kurkin, et al.
Published: (2023-05-01)